Drugs.com - New Drug Approvals

FDA Approves Osenvelt (denosumab-bmwo), a Biosimilar to Xgeva

JERSEY CITY, N.J., March 3, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Osenvelt (CT-P41, denosumab-bmwo), a biosimilar referencing Xgeva (denosumab), for all indications of the...

Mar 5, 2025 - 02:25
 0
FDA Approves Osenvelt (denosumab-bmwo), a Biosimilar to Xgeva
JERSEY CITY, N.J., March 3, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Osenvelt (CT-P41, denosumab-bmwo), a biosimilar referencing Xgeva (denosumab), for all indications of the...
Read More

Tags:

Previous Article

Mackage launches spring/summer 2025 campaign with Charlie Hunnam and Stella Maxwell

Next Article

FDA Approves Stoboclo (denosumab-bmwo), a Biosimilar to Prolia

Related Posts

FDA Approves Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

FDA Approves Symbravo (meloxicam and rizatriptan) for t...

Feb 9, 2025  0

Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients with Limited-Stage Small Cell Lung Cancer

Imfinzi Approved in the US as First and Only Immunother...

Feb 9, 2025  0

FDA Approves Miudella (copper intrauterine system) for the Prevention of Pregnancy

FDA Approves Miudella (copper intrauterine system) for ...

Feb 26, 2025  0